Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 75,479 call options on the stock. This represents an increase of 114% compared to the average daily volume of 35,245 call options.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP increased its position in shares of SELLAS Life Sciences Group by 23,550.0% during the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after purchasing an additional 2,704,007 shares in the last quarter. Geode Capital Management LLC increased its position in SELLAS Life Sciences Group by 168.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after buying an additional 1,379,988 shares in the last quarter. Millennium Management LLC raised its stake in SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock valued at $5,232,000 after buying an additional 1,073,147 shares during the last quarter. State Street Corp raised its stake in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after buying an additional 827,257 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in SELLAS Life Sciences Group by 535.7% in the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after acquiring an additional 540,748 shares in the last quarter. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock traded down $0.19 during trading hours on Thursday, reaching $9.91. The stock had a trading volume of 870,396 shares, compared to its average volume of 8,436,692. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -43.00 and a beta of 2.42. The business’s 50 day moving average price is $10.50 and its 200-day moving average price is $6.79. SELLAS Life Sciences Group has a 52 week low of $1.39 and a 52 week high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.